A R Zakaryaeva

Municipal Clinical Hospital named after V.V. Veresaev, Moscow, Russia.

2 publications 2023 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does A R Zakaryaeva research?

Dr. Zakaryaeva studies how well the medication Revelise (alteplase) works for patients who have experienced an ischemic stroke, which happens when a blood clot blocks blood flow to the brain. By observing real-life scenarios and outcomes from clinical trials, she aims to understand the medication's impact on reducing disabilities caused by strokes, especially in older patients and those with other health conditions. This research is vital for improving treatment protocols and ensuring doctors have effective options for their patients dealing with the aftermath of a stroke.

Key findings

  • In her study, 49.9% of the 2,202 patients had good outcomes at discharge, indicating they experienced significant recovery.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%, showing sustained improvement over time.
  • The results demonstrate that Revelise effectively reduces stroke-related disabilities, even for older patients and those with comorbidities.

Frequently asked questions

Does Dr. Zakaryaeva study ischemic strokes?
Yes, she specifically researches the treatment of ischemic strokes using the medication Revelise.
What is Revelise and how does it help stroke patients?
Revelise is a medication that helps dissolve blood clots in the brain, thereby improving blood flow and reducing disabilities related to strokes.
Is Dr. Zakaryaeva's work relevant to older stroke patients?
Absolutely, her research addresses the effectiveness of stroke treatment in older patients, emphasizing their recovery potential.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Experience of using a Russian alteplase product as thrombolytic therapy in patients with ischemic stroke in routine practice].

2023

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Murtazalieva DM, Zakaryaeva AR, Soshina TD, Zolotov MA, Parfenov VA

Plain English
This study looked at how well a drug called Revelisa works for treating ischemic stroke in 72 patients who received treatment within 4.5 hours of their stroke. The results showed significant improvements in patients' neurological scores, with 34.7% showing at least a 4-point improvement within 24 hours, and 68.1% achieving good recovery after 30 days. There were very few side effects, with only 5.6% experiencing minor bleeding and just one patient dying, indicating that Revelisa is both effective and safe for stroke treatment. Who this helps: This benefits patients suffering from ischemic stroke.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.